Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.43 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.42 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.42 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.42 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.42 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.38 |
| ▸ | BHMT | Q93088 | 1/20 | 0.37 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.37 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 2/20 | 0.36 |
| ▸ | GABRD | O14764 | 2/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21345666 | 1.00 | FFAR3 (0.43) | FFAR3GRIK1GRIA4GRIK3GRIK5 | |
| SCHEMBL16359636 | 1.00 | FFAR3 (0.43) | FFAR3GRIK1GRIA4GRIK3GRIK5 | |
| SCHEMBL13146871 | 0.81 | FFAR3 (0.46) | FFAR3GRIK1GRIA4GRIK3GRIK5 | |
| SCHEMBL14771690 | 0.80 | GRIK1 (0.38) | FFAR3GRIK1GRIA4GRIK3GRIK5 | |
| SCHEMBL21345146 | 0.80 | GRIK1 (0.38) | FFAR3GRIK1GRIA4GRIK3GRIK5 | |
| SCHEMBL16021873 | 0.80 | TDP1 (0.43) | FFAR3GRIK1GRIA4GRIK3GRIK5 | |
| Aspartic Acid SCHEMBL7781260 | 0.80 | GRIK1 (0.57) | FFAR3GRIK1GRIA4GRIK3GRIK5 | |
| SCHEMBL16024166 | 0.80 | ALDH1A1 (0.43) | FFAR3GRIK1GRIA4GRIK3GRIK5 | |
| Aspartic Acid SCHEMBL135731 | 0.80 | GRIK1 (0.57) | FFAR3GRIK1GRIA4GRIK3GRIK5 | |
| SCHEMBL10068031 | 0.80 | GRIK1 (0.38) | FFAR3GRIK1GRIA4GRIK3GRIK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365577-A1 | Photodynamic Therapy and Diagnosis | RMW CHO GROUP LIMITED (HK) | 2023-11-16 | — | — | US | disclosed |
| US-20170202941-A1 | OMPA AND ASP14 IN VACCINE COMPOSITIONS AND AS DIAGNOSTIC TARGETS | VIRGINIA COMMONWEALTH UNIVERSITY | 2017-07-20 | — | — | US | disclosed |
| US-20170190786-A1 | ANTI-ErbB2 ANTIBODIES | GENENTECH INC (US) | 2017-07-06 | — | — | US | disclosed |
| EP-2552966-B1 | ANTIBODIES AGAINST CSF-1R | IMCLONE LLC (US) | 2017-07-05 | — | — | EP | disclosed |
| US-20160369294-A9 | NUCLEOTIDE SEQUENCES AND CORRESPONDING POLYPEPTIDES CONFERRING MODIFIED PHENOTYPE CHARACTERISTICS IN PLANTS | CERES, INC. (US) | 2016-12-22 | — | — | US | disclosed |
| EP-2298800-B1 | Sclerostin binding antibodies | AMGEN INC (US) | 2016-11-30 | — | — | EP | disclosed |
| EP-2222709-B1 | ANTIGEN-BINDING CONSTRUCTS | GLAXO GROUP LTD (GB) | 2016-11-23 | — | — | EP | disclosed |
| EP-2793822-B1 | PERACID-GENERATING COMPOSITIONS | COLGATE PALMOLIVE CO (US) | 2016-08-24 | — | — | EP | disclosed |
| EP-2900254-B1 | ALPHA-1-MICROGLOBULIN FOR USE IN THE TREATMENT OF MITOCHONDRIA-RELATED DISEASES | A1M PHARMA AB (SE) | 2016-08-03 | — | — | EP | disclosed |
| EP-2622068-B1 | VARIANTS OF POLYPEPTIDES HAVING CELLULOLYTIC ENHANCING ACTIVITY AND POLYNUCLEOTIDES ENCODING SAME | NOVOZYMES INC (US) | 2016-07-20 | — | — | EP | disclosed |
| US-20110258004-A1 | Reconciliation , Automation and Tagging of Healthcare Information | REVENUE MANAGEMENT SOLUTIONS, LLC, FORMERLY KNOWN AS, RMS NEWCO, LLC | 2011-10-20 | — | — | US | disclosed |
| EP-2292647-A2 | Small Streptococcus pyogenes antigens and their use | Intercell AG (AT) | 2011-03-09 | — | — | EP | disclosed |
| US-20100035825-A1 | Treatment Of Disease By Inducing Cell Apoptosis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-02-11 | — | — | US | disclosed |
| US-20090098622-A1 | SCHIZOCHYTRIUM PKS GENES | MARTEK BIOSCIENCES CORPORATION (US) | 2009-04-16 | — | — | US | disclosed |
| US-7498436-B2 | Substituted hydroxyethylamines | PHARMACIA & UPJOHN COMPANY LLC (US) | 2009-03-03 | — | — | US | disclosed |
| WO-2008142366-A2 | METHODS FOR SELECTING OR DESIGNING MODULATORS, BASED ON THE CRYSTAL STRUCTURE OF LEUKOTRIENE C4 SYNTHASE (LTC4S) | BIOLIPOX AB (SE) | 2008-11-27 | — | — | WO | disclosed |
| US-7407677-B2 | Enzymes having alpha amylase activity and methods of use thereof | VERENIUM CORPORATION (US) | 2008-08-05 | — | — | US | disclosed |
| US-20080068284-A1 | Display Device | FUJITSU TEN LIMITED (JP) | 2008-03-20 | — | — | US | disclosed |
| US-7319134-B2 | Regulation of transcription factor, NF-IL6/LAP | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-01-15 | — | — | US | disclosed |
| US-20070275440-A1 | REGULATION OF TRANSCRIPTION FACTOR, NF-IL6/LAP | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365577-A1 | Photodynamic Therapy and Diagnosis | PPOX, PPIF, ALAD | FFAR3 3709/4885GRIK1 4694/4885GRIA4 4375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.